News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Johnson & Johnson (JNJ) reports robust sales growth and raises full-year guidance, despite facing headwinds from STELARA and challenges in the MedTech segment.
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...
Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.
Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State
Johnson and Johnson has quietly become one of the best-performing mega-caps of the past year, but with a fresh pullback and a pipeline firing on multiple cylinders, the bigger question is whether the next leg higher finally breaks through to record territory.
Find insight on Johnson & Johnson, Roche Holding, Novartis and more in the latest Market Talks covering health care.
Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare compounding opportunity depends on what the numbers actually say.
Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.
Johnson & Johnson (NYSE:JNJ) has surpassed US$100b in annual revenue for the first time in its 140-year history. The milestone follows strong Q2 2026 results and an increase to full-year revenue guidance. Performance was primarily driven by the company’s Innovative Medicine and MedTech segments. For investors following Johnson & Johnson, this US$100b revenue milestone highlights the scale of its global healthcare footprint across pharmaceuticals and medical devices. The company operates...
JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.
ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?
Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...
Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.
Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.
Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.
Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect
Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.
News of the day for July 15, 2026
Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year
The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint
Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
